A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.

Also called NCT07082114

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07082114
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07082114. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-14 (actual); primary completion 2027-02-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Intervention (Drug)
HDM1002 100 mg
Intervention (Drug)
HDM1002 200 mg
Intervention (Drug)
HDM1002 400 mg
Intervention (Drug)
Dapagliflozin (DAPA)
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07082114
Content hash
997b7baefd3cc8ef7f73465e4188695b2eec9f97149eb314c62b971927046a44